Seeking Alpha·Sep 16, 2026
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical faces a challenging path to profitability as its regenerative medicine commercialization efforts struggle to overcome high SG&A costs, which frequently exceed total revenue. While the company maintains gross margins above 80%, the lack of consist...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.25+14.6% vs -$0.29 | $21M+6.1% vs $20M |
Q2 2026 May 14, 2026 | -$0.35+0.0% vs -$0.35 | $19M+5.2% vs $18M |
Q1 2026 Feb 12, 2026 | -$0.38-4.3% vs -$0.36 | $17M-2.3% vs $18M |
Q4 2025 Nov 6, 2025 | -$0.46-7.0% vs -$0.43 | $17M-36.5% vs $27M |
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer | New York Morgan Stanley 24th Annual Global Healthcare Conference – Wednesday, September 16, 2026 | 1:05 p.m.
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Benchmark RCEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avita Medical Inc. (RCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.95 | $272.03M | -6.29 | 11.45% | -67.85% | — | — | |
| $0.38 | $52.6M | 12.50 | 14.21% | -10.17% | -23.45% | — | |
| $1.30 | $58.16M | -1.57 | 15.84% | -51.53% | — | — | |
| $4.77 | $695.28M | 14.91 | 19.99% | 1.76% | 2.61% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $2.95 | $124.23M | -10.93 | 9.86% | -14.78% | -76.6% | — |
Avita Medical Inc. (RCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avita Medical Inc. (RCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Aug 6, 2026·SEC
Jun 8, 2026·SEC
Get notified when RCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avita Medical Inc. (RCEL) stock FAQ — growth, dividends, profitability & financials explained
Avita Medical Inc. (RCEL) reported $75.6M in revenue for fiscal year 2025.
Avita Medical Inc. (RCEL) grew revenue by 11.5% over the past year. This is steady growth.
Avita Medical Inc. (RCEL) reported a net loss of $43.1M for fiscal year 2025.
Avita Medical Inc. (RCEL) had negative free cash flow of $23.6M in fiscal year 2025, likely due to heavy capital investments.
